Required Pre-Conference Reading
Making Faster Progress in Ovarian Cancer: New Research Directions an Business Models
Additional Readings
To make the most of our time together, we’ve compiled a short list of readings you may find helpful in preparing for discussions.
- A mathematical-descriptor of tumor-mesoscopicstructure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer, Haonan Lu et al. 2019, Nature Communications 10.
- A portfolio approach to accelerate therapeutic innovation in ovarian cancer, Shomesh Chaudhuri et al. 2019 Journal of Investment Management 17, pp. 1-12.
- Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores, Ryan Spencer et al. 2019 Gynecologic Oncology 152, pp 106-111.
- Epithelial ovarian cancer, Stephanie Lheureux et al. 2019 Lancet 393 pp.1240–53
- Financing translation: Analysis of the NCATS rare-diseases portfolio, David E. Fagnan et al. 2015 Science Translational Medicine 7 pp. 276-276ps3.
- Impact Investing Could Accelerate the Fight Against Cancer, Richard G. Hamermesh and Kathy Giusti. 2018 Harvard Business Review.
- Kathy Giusti and the Multiple Myeloma Research Foundation, Richard G. Hamermesh et al. 2014 Harvard Business School.
- Ovarian cancer, Ursula A. Matulonis et al. 2016 Nature Reviews Disease Primers v2.
- Ovarian cancers: evolving paradigms in research and care Report in Brief and Recommendations, National Academy of Sciences 2016.
- Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program, Sonya Das and Andrew W. Lo 2017, Contemporary Clinical Trials 62 pp. 168-174.
- Venture Philanthropy: A Case Study of the Cystic Fibrosis Foundation, Esther S. Kim and Andrew W. Lo 2019 SSRN.